Hereditary angioedema is characterised by unpredictable, painful and potentially life-threatening oedema. Recently, some C1 inhibitors have been approved for self-administration and/or routine prevention, enabling patients to be proactive in managing their disease and reducing the burden of illness. This article discusses the effect of these advances from a specialist nurse’s perspective.
Nursing Standard. 27, 37, 35-40. doi: 10.7748/ns2013.05.27.37.35.e7336
Correspondencejohn.dempster@bartshealth.nhs.uk
Peer reviewThis article has been subject to double blind peer review
Conflict of interestThe author has performed consultancy work for CSL Behring, Shire and ViroPharma. Medical writing assistance was provided by Shilpa Aggarwal, ApotheCom ScopeMedical, funded by ViroPharma Ltd.
Accepted: 14 January 2013
or
Alternatively, you can purchase access to this article for the next seven days. Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
